*Median reduction vs placebo.
† In a 32-week crossover study, patients ≥12 years of age with symptomatic type 1 or 2 HAE (N=90) were randomly assigned to twice-weekly treatment with HAEGARDA 40 IU/kg or 60 IU/kg. Patients initiated 16 weeks of active treatment or placebo and crossed over to placebo or active treatment for the subsequent 16 weeks. Baseline HAE attack frequency was 8.8 in the 3 months before screening for the 60 IU/kg group.1
‡ The WAO Guideline for the Management of HAE states that patients should have HAE rescue medication available at all times.2 >
Steady state is expected within 3 to 4 doses1
* The plasma levels of C1-INH functional activity were evaluated in patients with type 1 or type 2 HAE in a Phase 3, placebo-controlled, crossover study. Patients received twice-weekly subcutaneous injections of HAEGARDA 40 IU/kg or 60 IU/kg for 16 weeks. The model-derived outcome is the steady-state C1-INH functional activity vs time.3
|Injection-site reaction*||27 (31%)||21 (24%)|
|Nasopharyngitis||9 (11%)||6 (7%)|
|Hypersensitivity†||5 (6%)||1 (1%)|
|Dizziness||4 (5%)||1 (1%)|
*Includes bruising, coldness, discharge, erythema, hematoma, hemorrhage, induration, edema, pain, pruritus, rash, injection-site reaction, scarring, swelling, urticaria, and warmth at the injection site.
†Includes hypersensitivity, pruritus, rash, and urticaria.
‡Includes patients who were treated with 40 IU/kg and 60 IU/kg.
NO THROMBOEMBOLIC EVENTS with HAEGARDA in clinical trials
|Patient Weight||HAEGARDA Dosage||Injection Volume|
|75 lb (34 kg)||2040 IU||4.1 mL|
|100 lb (45 kg)||2700 IU||5.4 mL|
|150 lb (68 kg)||4080 IU||8.2 mL|
|175 lb (80 kg)||4800 IU||9.6 mL|
HAEGARDA Connect provides patient support from 8AM to 8PM ET. 1-844-HAEGARDA (1-844-423-4273)
When enrolled, patients will be introduced to a range of programs, such as:
Co-pay assistance for commercially insured patients
A temporary assistance program for those who experience a gap or change in insurance coverage
Patient assistance for people who do not have coverage
For more information about HAEGARDA Connect, visit the Patient Website